Common Contracts
21 similar Sales Agreement contracts by MICROSTRATEGY Inc, Aclaris Therapeutics, Inc., Beam Therapeutics Inc., others
SOLID BIOSCIENCES INC. Shares of Common Stock (par value $0.001 per share) AMENDED AND RESTATED SALES AGREEMENTSales Agreement • March 13th, 2024 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
Solid Biosciences Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
BEAM THERAPEUTICS INC. SALES AGREEMENTSales Agreement • February 28th, 2024 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
SALES AGREEMENTSales Agreement • February 23rd, 2024 • ImmunoPrecise Antibodies Ltd. • Pharmaceutical preparations • New York
ImmunoPrecise Antibodies Ltd., a corporation continued under the Business Corporations Act (British Columbia) (the "Company"), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Clear Street LLC, as sales agent and/or principal (the "Agent"), common shares of the Company, without par value (the "Common Shares"), on the terms set forth in this agreement (this "Agreement").
SALES AGREEMENTSales Agreement • January 2nd, 2024 • Cibus, Inc. • Agricultural chemicals • New York
SALES AGREEMENTSales Agreement • November 30th, 2023 • MICROSTRATEGY Inc • Services-prepackaged software • New York
SALES AGREEMENTSales Agreement • September 29th, 2023 • Inventiva S.A. • Pharmaceutical preparations • New York
The undersigned, the duly qualified and elected Chief Executive Officer of Inventiva S.A., a société anonyme incorporated in France (the “Company”), does hereby certify in such capacity and on behalf of the Company, pursuant to Section 4(p) of the Sales Agreement, dated September 28, 2023, between the Company and Cowen and Company, LLC (the “Sales Agreement”), that to the knowledge of the undersigned:
SALES AGREEMENTSales Agreement • August 1st, 2023 • MICROSTRATEGY Inc • Services-prepackaged software • New York
SALES AGREEMENTSales Agreement • June 30th, 2023 • Vince Holding Corp. • Retail-apparel & accessory stores • New York
SALES AGREEMENTSales Agreement • May 1st, 2023 • MICROSTRATEGY Inc • Services-prepackaged software • New York
SALES AGREEMENTSales Agreement • March 30th, 2023 • Bed Bath & Beyond Inc • Retail-home furniture, furnishings & equipment stores • New York
ACLARIS THERAPEUTICS, INC. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENTSales Agreement • February 23rd, 2023 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • New York
Esperion Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • February 21st, 2023 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
SALES AGREEMENTSales Agreement • September 9th, 2022 • MICROSTRATEGY Inc • Services-prepackaged software • New York
SALES AGREEMENTSales Agreement • August 2nd, 2021 • Inventiva S.A. • Pharmaceutical preparations • New York
The undersigned, the duly qualified and elected Chief Executive Officer of Inventiva S.A., a société anonyme incorporated in France (the “Company”), does hereby certify in such capacity and on behalf of the Company, pursuant to Section 4(p) of the Sales Agreement, dated August 2, 2021, between the Company and Jefferies LLC (the “Sales Agreement”), that to the knowledge of the undersigned:
ACLARIS THERAPEUTICS, INC. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENTSales Agreement • May 20th, 2021 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • New York
BEAM THERAPEUTICS INC. SALES AGREEMENTSales Agreement • April 1st, 2021 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
SALES AGREEMENTSales Agreement • March 29th, 2021 • Cellectis S.A. • Biological products, (no disgnostic substances) • New York
SALES AGREEMENTSales Agreement • November 10th, 2020 • BioNTech SE • Biological products, (no disgnostic substances) • New York
par value $0.001 per share) AMENDED AND RESTATED SALES AGREEMENTSales Agreement • May 7th, 2020 • Kala Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
UROGEN PHARMA LTD. ORDINARY SHARES SALES AGREEMENTSales Agreement • December 20th, 2019 • UroGen Pharma Ltd. • Pharmaceutical preparations • New York
SOLID BIOSCIENCES INC. Shares of Common Stock (par value $0.001 per share) SALES AGREEMENTSales Agreement • March 13th, 2019 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
